WuXi Biologics offers Biologics structure, higher-order structure, potency, release and stability. This is the analytical service business of an integrated CRO/CDMO.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY IFRS / consolidated
21,790,018,000
4,908,343,000 Net income/(loss) attributable to owners of the parent
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: CNY thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
WuXi XDC is consolidated within WuXi Biologics. Revenue of the two listed entities must not be added to estimate industry totals.
Adjusted profit is a non-IFRS measure. This record uses adjusted profit attributable to owners of the company, distinct from total adjusted group profit.
2026H1 · Reporting notes
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: CNY thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
WuXi XDC is consolidated within WuXi Biologics. Revenue of the two listed entities must not be added to estimate industry totals.
Adjusted profit is a non-IFRS measure. This record uses adjusted profit attributable to owners of the company, distinct from total adjusted group profit.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Biologics structure, higher-order structure, potency, release and stability
Integrated CRO/CDMO analytical services
Provides biologics discovery, development, and manufacturing CRDMO services. Consolidated financials include the separately listed WuXi XDC.
Listed as HKEX 02269; original 2025 annual and 2026H1 reports reviewed.
Program / service
Target / indication
Representative stage
Evidence & scope
Biologics CRDMO
Not applicable (services/platform) · Drug research and manufacturing services for clients
Services / platform
Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
FDA announced final guidance on potency assurance for cellular and gene therapies on November 2. Its recommendations integrate manufacturing-process design, material and process controls, in-process testing, and lot-release potency assays. The agency emphasizes product-specific, risk-based strategies across development and commercialization; this is final guidance, not approval of any individual therapy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
Financials are consolidated figures for the listed group. Revenue by service line, available capacity, and project fit require further verification at the segment and operating-entity levels.
The group consolidates WuXi XDC. Figures for the listed parent and subsidiary must not be added together.
